Envafolimab with doxorubicin and ifosfamide for advanced soft tissue sarcoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 2 interventional trial testing subcutaneous envafolimab combined with standard doxorubicin-plus-ifosfamide chemotherapy in adults with previously untreated advanced soft tissue sarcoma and at least one measurable lesion. Participants receive scheduled cycles of the AI chemotherapy alongside regular envafolimab injections, with safety, lab tests, and radiographic tumor response monitored throughout treatment. The combination is based on the idea that anthracyclines can cause immunogenic cell death and increase PD-L1 expression, potentially enhancing the effect of PD-L1 blockade. The single-center study is conducted at the Second Affiliated Hospital, Zhejiang University School of Medicine and tracks objective responses and treatment-related adverse events.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Pathologically confirmed advanced soft tissue sarcoma with at least one measurable lesion.
2. No previous systemic treatment.
3. ≥18 years old; expected survival time more than 3 months;
4. Major organ function within 7 days before treatment, meeting the following criteria:

(1) Routine blood test criteria (without blood transfusion within 14 days):

* Hemoglobin (HB) ≥90g/L; ② Absolute neutrophil count (ANC) ≥1.5×109/L; ③ Platelet count (PLT) ≥80×109/L. (2) Biochemical examinations must meet the following criteria: ① Total bilirubin (TBIL) ≤ 1.5 times the upper limit of normal (ULN); ② Alanine aminotransferase (ALT) and aspartate aminotransferase AST ≤ 2.5 ULN. If liver metastasis is present, ALT and AST ≤ 5 ULN; ③ Serum creatinine (Cr) ≤ 1.5 ULN or creatinine clearance (CCr) ≥ 60ml/min; (3) Doppler ultrasound assessment: left ventricular ejection fraction (LVEF) ≥ lower limit of normal (50%). 5. Women of childbearing age must agree to use contraceptive measures (such as intrauterine devices, birth control pills or condoms) during the study and within 6 months after the study; serum or urine pregnancy tests must be negative within 7 days before study enrollment, and the patients must not be breastfeeding; men must agree to use contraceptive measures during the study and within 6 months after the study.

Exclusion Criteria:

1. Chondrosarcoma (CS), osteosarcoma (OS), Ewing's sarcoma, dermatofibrosarcoma protuberans (DFSP), and gastrointestinal stromal sarcoma (GIST) are excluded;
2. Pregnant or lactating women, or women of childbearing potential who are not using contraceptive measures;
3. Current severe, uncontrolled acute infection; or purulent or chronic infection with a persistent wound;
4. Presence of a second primary tumor (excluding basal cell carcinoma of the skin);
5. Participation in other drug clinical trials within 4 weeks;
6. Presence of severe heart disease, including congestive heart failure, uncontrolled high-risk arrhythmias, unstable angina, myocardial infarction, severe valvular heart disease, and refractory hypertension;
7. Suffering from uncontrolled neurological, psychiatric, or mental disorders, poor compliance, and inability to match the medication. Patients with uncontrolled primary brain tumors or central nervous system metastases and significant intracranial hypertension or neuropsychiatric symptoms are excluded.
8. Evidence of a hereditary bleeding diathesis or coagulopathy.
9. A history of severe allergic/anaphylactic reactions to humanized antibodies.
10. Diagnosed with immunodeficiency or receiving systemic glucocorticoids or any other form of immunosuppressive therapy within 14 days prior to the first dose of the study drug. Physiological doses of glucocorticoids (≤10 mg/day of prednisone or equivalent) are permitted.
11. Subjects with active, known, or suspected autoimmune diseases (e.g., interstitial pneumonitis, colitis, hepatitis, hypophysitis, vasculitis, nephritis, including but not limited to these diseases or syndromes) are excluded.

Where it's running

• Department of Medical Oncology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
  Hanzhong, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Ying Dong
• Email: dongying74@zju.edu.cn
• Phone: +8113666669105

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Single-protein encapsulated doxorubicin (SPEDOX-6) for advanced solid tumors

  We will try SPEDOX-6, a protein-encapsulated form of doxorubicin, to find a safe dose and see if it helps adults with advanced, treatment-resistant solid tumors (including certain sarcomas, triple-negative breast cancer, non-small cell lung cancer, cervical, ovarian, and KRAS‑mutant pancreatic cancers) who have not rec

  Recruiting Phase 1/2 University of California, Irvine · Orange, California · NCT07064018

• Neoadjuvant atezolizumab and doxorubicin with preoperative radiation and adjuvant atezolizumab for high‑risk resectable limb and trunk soft tissue sarcoma

  This will test whether adding the immunotherapy atezolizumab to doxorubicin chemotherapy before surgery, with radiation before surgery and more atezolizumab after surgery, can delay relapse in adults with high‑risk, resectable soft tissue sarcoma of the arms, legs, or trunk.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07049848

• Combining Anlotinib with Doxorubicin and Radiotherapy for Soft Tissue Sarcoma Treatment

  This study is testing if combining a cancer drug called anlotinib with chemotherapy and radiation can help people with high-grade soft tissue sarcoma have better treatment results before surgery.

  Recruiting at 2 sites Phase 4 Guangdong Provincial People's Hospital · Guangzhou, Guangdong and 1 other locations · NCT06506838

• Sequential chemotherapy for soft tissue sarcoma

  This study tests if giving two types of chemotherapy before surgery can help people with high-grade soft tissue sarcoma live longer and be cancer-free.

  Recruiting at 2 sites Phase 2 Oslo University Hospital · Bergen and 1 other locations · NCT04776525

• 68Ga-HX01 PET/CT Imaging in Soft Tissue Sarcoma patients

  This study tests whether a 68Ga-HX01 injection can help PET/CT imaging better characterize soft tissue sarcoma in adults who have exhausted standard treatments or have no good options.

  Recruiting Phase 2 Hexin (Suzhou) Pharmaceutical Technology Co., Ltd · Wuhan, Hubei · NCT07920835

• Zemetostat plus Anlotinib for SWI/SNF-deficient Head and Neck Soft Tissue Sarcoma

  This trial tests whether zemetostat plus anlotinib can help people with recurrent or metastatic head-and-neck soft tissue sarcoma that has SWI/SNF complex deficiency after standard therapy fails.

  Recruiting Phase 2 Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University · Shanghai, Shanghai Municipality · NCT07917949

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.